Pharma News

Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

Designing a vaccine starts with finding the right ingredients. Every infectious agent has molecules, called antigens, that the immune system could potentially recognize and attack. So scientists must carefully consider which antigens should go into a vaccine.

New findings from a large European study of patients in 18 countries, including the UK, show that while many patients are able to reduce their risk through taking statins, those at the highest risk of cardiovascular events may benefit from combinations of lipid-lowering therapies.